{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:33Z","timestamp":1791520833987,"version":"4.3.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Aldosterone synthase (CYP11B2) is overexpressed in primary aldosteronism (PA), making it a promising target for imaging. This first-in-human study evaluates the safety and feasibility of [<jats:sup>18<\/jats:sup>F]AldoView, a highly selective PET tracer targeting CYP11B2, for PA subtyping.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Biodistribution and dosimetry of [<jats:sup>18<\/jats:sup>F]AldoView were assessed in 3 healthy volunteers using whole-body PET\/CT. Fifteen patients with adrenal lesions (13 with PA, 1 with Cushing\u2019s syndrome, and 1 with a nonfunctional adenoma) were enrolled. PET\/CT scans were performed 60 minutes postinjection. Lesions were considered positive if tracer uptake exceeded normal adrenal tissue. Semi-quantitative analyses included maximum standardized uptake value (SUVmax), lesion-to-liver ratio (LLR), and lesion-to-adrenal ratio (LAR). Ten PA patients with positive imaging findings and 1 with Cushing\u2019s syndrome underwent adrenalectomy, and resected specimens were analyzed for CYP11B2 expression. This ongoing study is registered with the Chinese Clinical Trial Registry (ChiCTR2400093214).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>[<jats:sup>18<\/jats:sup>F]AldoView was well-tolerated, with no adverse events. The effective dose was 0.012\u00b10.0022\u00a0mSv\/MBq. PET\/CT identified positive lesions in all 10 PA patients, with a mean SUVmax of 15.73\u00b18.57, LAR of 8.02\u00b14.06, and LLR of 10.24\u00b11.48. No positive lesions were observed in patients with idiopathic hyperaldosteronism, Cushing\u2019s syndrome, or nonfunctional adenomas. Positive lesions showed strong CYP11B2 staining on pathology, confirming aldosterone-producing adenomas (APA) or nodules (APN).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>[<jats:sup>18<\/jats:sup>F]AldoView PET\/CT is safe and feasible for the imaging of APAs and APNs in PA patients. These results highlight its potential for noninvasive in vivo detection of CYP11B2, supporting its use in PA subtyping.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006014","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:06:23Z","timestamp":1749139583000},"page":"847-855","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["First-in-Human Evaluation of [18F]AldoView: A Highly Selective PET Tracer for Aldosterone Synthase Imaging in Primary Aldosteronism"],"prefix":"10.1097","volume":"50","author":[{"given":"Tingting","family":"Long","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geru","family":"Liu","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1933-3920","authenticated-orcid":false,"given":"Huizhu","family":"Chen","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6197-1359","authenticated-orcid":false,"given":"Ning","family":"Peng","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Jin","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"He","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-6158","authenticated-orcid":false,"given":"Yu","family":"Gan","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Liu","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Guo","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuying","family":"Xia","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghang","family":"Luo","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3580-1200","authenticated-orcid":false,"given":"Tiejian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"},{"name":"National Clinical Research Center for Geriatric Diseases"},{"name":"Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.surg.2020.09.005","article-title":"Minimally invasive partial versus total adrenalectomy for unilateral primary hyperaldosteronism\u2014a retrospective, multicenter matched-pair analysis using the new international consensus on outcome measures","volume":"169","author":"Billmann","year":"2021","journal-title":"Surgery"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.123.21910","article-title":"Multifocal, asymmetric bilateral primary aldosteronism cannot be excluded by strong adrenal vein sampling lateralization: an international retrospective cohort study","volume":"81","author":"Turcu","year":"2024","journal-title":"Hypertension"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1210\/clinem\/dgae142","article-title":"Contralateral suppression in adrenal venous sampling predicts clinical and biochemical outcome in primary aldosteronism","volume":"109","author":"Okubo","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"e2338209","DOI":"10.1001\/jamanetworkopen.2023.38209","article-title":"Corticotropin stimulation in adrenal venous sampling for patients with primary aldosteronism: the ADOPA randomized clinical trial","volume":"6","author":"Yang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/clinem\/dgad421","article-title":"The value of targeting CXCR4 with 68Ga-pentixafor PET\/CT for subtyping primary aldosteronism","volume":"109","author":"Zheng","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"e2255609","DOI":"10.1001\/jamanetworkopen.2022.55609","article-title":"Accuracy of Gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism","volume":"6","author":"Hu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-0043-122238","article-title":"Disordered CYP11B2 expression in primary aldosteronism","volume":"49","author":"Gomez-Sanchez","year":"2017","journal-title":"Horm Metab Res"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO Classification of Adrenal Cortical Tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/EJE-20-0532","article-title":"Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism","volume":"183","author":"Soinio","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1210\/endrev\/bnad026","article-title":"Treating primary aldosteronism-induced hypertension: novel approaches and future outlooks","volume":"45","author":"Mullen","year":"2024","journal-title":"Endocr Rev"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"[(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","article-title":"Development of [(18)F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism","volume":"64","author":"Sander","year":"2021","journal-title":"J Med Chem"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00259-022-05957-9","article-title":"First-in-human evaluation of [(18)F]CETO: a novel tracer for adrenocortical tumours","volume":"50","author":"Silins","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s00259-020-04722-0","article-title":"Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism","volume":"47","author":"Ding","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-024-01109-2","article-title":"Radiation dosimetry of para-chloro-2-[(18)F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging","volume":"14","author":"Silins","year":"2024","journal-title":"EJNMMI Res"},{"key":"R24-20250731","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.123.266061","article-title":"Clinical value of (68)Ga-Pentixafor PET\/CT in subtype diagnosis of primary aldosteronism patients with adrenal micronodules","volume":"65","author":"Ding","year":"2024","journal-title":"J Nucl Med"},{"key":"R25-20250731","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268425","article-title":"A phase I\/IIa clinical trial to evaluate safety and adrenal uptake of para-chloro-2-[(18)F]Fluoroethyletomidate in healthy volunteers and patients with primary aldosteronism","author":"Gillett","year":"2025","journal-title":"J Nucl Med"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/RLU.0000000000004244","article-title":"Usefulness of 68 Ga-Pentixafor PET\/CT on diagnosis and management of Cushing syndrome","volume":"47","author":"Ding","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients","volume":"42","author":"Bluemel","year":"2017","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:18Z","timestamp":1753938018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006014","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2025-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}